Thorax Centre, Erasmus Medical Centre, Rotterdam, the Netherlands.
Eur Heart J. 2014 Mar;35(12):765-76. doi: 10.1093/eurheartj/eht542. Epub 2013 Dec 23.
Current generation of drug-eluting stents has significantly improved the outcomes of percutaneous coronary intervention by substantially reducing in-stent restenosis and stent thrombosis. However, a potential limitation of these stents is the permanent presence of a metallic foreign body within the artery, which may cause vascular inflammation, restenosis, thrombosis, and neoatherosclerosis. The permanent stents also indefinitely impair the physiological vasomotor function of the vessel and future potential of grafting the stented segment. Bioresorbable scaffolds (BRSs) have the potential to overcome these limitations as they provide temporary scaffolding and then disappear, liberating the treated vessel from its cage and restoring pulsatility, cyclical strain, physiological shear stress, and mechanotransduction. While a number of BRSs are under development, two devices with substantial clinical data have already received a Conformité Européenne marking. This review article presents the current status of these devices and evaluates the challenges that need to be overcome before BRSs can become the workhorse device in coronary intervention.
当前一代的药物洗脱支架通过显著降低支架内再狭窄和支架内血栓形成,显著改善了经皮冠状动脉介入治疗的结果。然而,这些支架的一个潜在局限性是动脉内永久存在金属异物,这可能导致血管炎症、再狭窄、血栓形成和新动脉粥样硬化。永久性支架还会无限期地损害血管的生理性血管舒缩功能和未来对支架节段进行移植的潜力。生物可吸收支架 (BRS) 有潜力克服这些局限性,因为它们提供临时支架,然后消失,使受治疗的血管从其笼中解脱出来,并恢复搏动性、周期性应变、生理性切应力和机械转导。虽然有许多 BRS 正在开发中,但已经有两种具有大量临床数据的设备获得了欧洲合格认证。本文介绍了这些设备的现状,并评估了在 BRS 成为冠状动脉介入治疗的主力设备之前需要克服的挑战。